pursuant to regulation 30 & 33 of Securities and Exchange Board of India, LODR, the Board of Directors at its meeting held on 11th August, 2025 have approved the unaudted financial result ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pentokey Organy reported a sharp jump in business activity for Q1 FY26. Revenue from operations rose to ₹506.20 lakhs, compared with just ₹60.62 lakhs in Q4 FY25 and only ₹0.00 lakhs in Q1 FY25; full-year FY25 revenue was ₹82.62 lakhs. Total income stood at ₹510.20 lakhs against total expenses of ₹461.73 lakhs, yielding a pre-tax and post-tax profit of ₹48.47 lakhs versus ₹4.60 lakhs in the year-ago quarter. Basic and diluted EPS came in at ₹0.99, up from ₹0.07 a year earlier. Total comprehensive income for the quarter was ₹62.19 lakhs, while reserves stood at ₹318.46 lakhs. The statutory auditor (Verma Mehta & Associates) issued an unmodified limited review report, and results pertain to the company's pharma/pesticides trading segment. A pending income tax demand of ₹171.58 lakhs for AY 2015-16, under appeal, was disclosed.
This is a strong quarter on paper — revenue and profit have multiplied several times over year-ago and sequential levels, which should be viewed positively by shareholders. However, the very low base and the lumpy nature of trading revenue (Q1 FY25 had near-zero revenue) mean investors should watch whether this scale of business is sustained in coming quarters before drawing firm conclusions.